21 results
8-K
EX-4.1
PMCB
PharmaCyte Biotech Inc
15 Nov 23
New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value
8:45pm
8-K
EX-4.2
PMCB
PharmaCyte Biotech Inc
15 Nov 23
New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value
8:45pm
8-K
EX-4.1
PMCB
PharmaCyte Biotech Inc
11 May 23
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000
8:30am
10-K
2022 FY
EX-4.2
PMCB
PharmaCyte Biotech Inc
Annual report
28 Jul 22
5:29pm
8-K
EX-4.3
PMCB
PharmaCyte Biotech Inc
23 Aug 21
PharmaCyte Biotech Announces $70 Million Registered Direct Offering
6:01am
8-K
EX-4.2
972d0p9ma1 ie6
23 Aug 21
PharmaCyte Biotech Announces $70 Million Registered Direct Offering
6:01am
8-K
EX-4.1
3hpli f8903
23 Aug 21
PharmaCyte Biotech Announces $70 Million Registered Direct Offering
6:01am
8-K
EX-4.1
w1lwreusujf
11 Aug 21
PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering
9:58pm
8-K
EX-4.3
jh66mze1g gopzapoj
11 Aug 21
PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering
9:58pm
8-K
EX-4.2
a2bkdot zlqn0b
11 Aug 21
PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering
9:58pm
8-K
EX-4.2
8w2 xlg63nk2
12 Jan 16
Entry into a Material Definitive Agreement
12:00am
8-K
EX-4.1
y8dhv qibw3kh9
12 Jan 16
Entry into a Material Definitive Agreement
12:00am
S-3
EX-4.4
3ue8pk
17 Oct 14
Shelf registration
12:00am
S-3
EX-4.3
r6k51l1j7
17 Oct 14
Shelf registration
12:00am
8-K
EX-4.1
fa4l6 hl5r8slp3w
29 May 14
Nuvilex Enters into an At the Market Banking Agreement with Chardan Capital Markets
12:00am
8-K
EX-4.1
ej51r7ft6t
19 Feb 14
Nuvilex Announces $27 Million Funding Commitment with Institutional Investor to Advance Late Phase Clinical Trials
12:00am